R&D channel feed – Endpoints News

R&D channel feed

Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful

9 years ago

Incyte turns to Penn for a collaboration on next-gen cancer combos

9 years ago

Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction

9 years ago

Cyclacel unveils a flop in leukemia 2 years after a call on futility, but still won’t give up

9 years ago

Argos’ PhIII for its personalized cancer vaccine implodes during an interim analysis

9 years ago

Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII

9 years ago

Cidara shares tank after lead antifungal program flops in PhII

9 years ago

Trevena says its PhIII pain drug program is a winner, but shares crater

9 years ago

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

9 years ago

AstraZeneca throws down the gauntlet with a PhIII victory in head-to-head PARP war with Tesaro

9 years ago

ArQule’s lead drug tivantinib flops again in PhIII liver cancer study

9 years ago

Ardelyx touts a PhIII hyperphosphatemia success for tenapanor, looking to calm fears over diarrhea

9 years ago

Merck’s HIV drug doravirine looks solid — though far less stellar than rivals — in 1st PhIII

9 years ago

Merck’s leading PhIII BACE drug implodes in latest Alzheimer’s disaster

9 years ago

Agenus pockets a fast $80M in cash and hands the R&D keys over to Incyte

9 years ago

Gilead proves it's one tough contender in HIV, but don't count GSK out of the fight

9 years ago

Aviragen Therapeutics slammed again by its second trial failure in days, this time for their lead drug

9 years ago

Sage shares get a bump from a snapshot of new PhII depression data

9 years ago

Zosano shares soar as its pivotal migraine drug patch study comes through

9 years ago

Axovant races to PhIII dementia study as nelotanserin clears an early hurdle, but questions linger

9 years ago

Intercept ‘lowers the bar’ on its pivotal PhIII OCA study for NASH

9 years ago

Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK

9 years ago

Daiichi Sankyo shutters another R&D center in an ongoing global overhaul

9 years ago

Neurocrine adds a Parkinson’s drug to its late-stage pipeline in $145M deal

9 years ago

First page Previous page 305 306 307308309 310 311 Next page Last page